Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY19 Earnings Presentation
11 slides from Eris Lifesciences's earnings presentation, Jan 29, 2019
Slide 1: Exchange filing cover letter: Investor Presentation
Date: 29th January, 2019 To To The Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATIO
Slide 2: Q3 19 Investor Presentation
Eris Q3 19 Investor Presentation
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: Patient Care Initiatives
PATIENT CARE INITIATIVES IMPROVING HEALTH OUTCOMES PATIENT CARE – the core of our business model. The aim is to improve health outcomes and the doctor – patient relationship with detailed data Identifying gaps in the healthcare delivery ecosystem and addressing those gaps with unique patient care in
Slide 5: India Heart Study
INDIA HEART STUDY To generate the first biggest epidemiological data in the country on Office and Home Blood Pressure Measurement 4
Slide 6: Medtronic Partnership
MEDTRONIC PARTNERSHIP Eris Lifesciences joins hands with Medtronics for diabetes monitoring • In a first of its kind collaboration, Eris Lifesciences has tied up with US medical devices maker Medtronics to bring the latter's technology to test glucose variability in diabetes patients • Medtronic wil
Slide 7: Financial Performance: Q3 FY19
RESULTS FINANCIAL PERFORMANCE: Q3 FY 19 INR millions Q3 FY 18 Q3 FY 19 yoy GR Sale of Products 2,075 2,485 20% Other Operating Income 15 39 Revenue from Operations 2,090 2,524 21% Gross Profit 1,753 2,130 22% Gross Profit Margins 84% 84% Employee cost 428 475 11% as % of Revenue 20% 19% Other Expens
Slide 8: Financial Performance: Q3 FY19
RESULTS FINANCIAL PERFORMANCE: Q3 FY 19 INR millions Q3 FY 18 Q3 FY 19 yoy GR Sale of Products 2,075 2,485 20% Other Operating Income 15 39 Revenue from Operations 2,090 2,524 21% EBITDA 811 935 15% EBITDA margin 39% 37% Depreciation and Amortisation * 67 96 43% EBIT 744 839 13% EBIT margin 36% 33%
Slide 9: FY19 Growth Trend and Productivity
FY 19 - Growth Trend and Productivity ERIS Quarterly Revenue INR mn 3,000 2,642 2,491 2,508 2,524 2,500 2,090 2,122 2,000 1,500 1,000 500 - Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 IPM Rank and Productivity IPM Rank * MRs YPM Lacs per month 24 2,022 4.1 Source: Internal numbers 8 * Source: AIOCD AWACS De
Slide 10: Q3 FY19 Entity Wise Growth
Q3 FY 19 Entity Wise Growth INR million Q3 FY 19 % of Total yoy GR IPM 3,39,862 100% 10% ERIS Consol 3,061 100% 11% Eris 2,351 77% 14% Strides 535 17% 16% Kinedex 119 4% -35% Aprica 56 2% 14% Source: AIOCD AWACS 9
Slide 11: Thank You
Eris THANK YOU